Research Information Only — Content is for educational purposes only and does not constitute medical advice. These compounds are not FDA-approved for the indications discussed. Consult a qualified physician before use.
A curated research collection covering the peptides with the strongest evidence base for wound healing, skin regeneration, and connective tissue repair — from the endogenous copper tripeptide that declines with age to the synthetic stabilization of thymosin β4's actin-binding fragment.
5
Compounds Profiled
3
With RCT Evidence
1973
GHK-Cu Discovery Year
4,000+
Genes · GHK Array
Shared Mechanisms Across Hub Compounds
🔧
Extracellular Matrix Remodeling
GHK-Cu, BPC-157, and TB-500 all modulate collagen deposition and ECM architecture — via fibroblast activation, MMP regulation, and growth factor induction respectively
🩸
Angiogenesis & Vascularization
BPC-157 (VEGFR2/NO pathway), TB-500 (VEGF-A upregulation), and GHK-Cu (VEGF induction from macrophages) all promote new vessel formation critical for wound healing
TGF-β, bFGF, EGF, and VEGF are convergently induced across hub compounds — each through distinct receptor or transcriptional mechanisms, explaining the additive effects seen in combination protocols
Compound Collection
Hub Compounds — Full Research Profiles
Each compound profile covers mechanism of action, clinical evidence, pharmacokinetics, dosing protocols, candidate selection criteria, and FAQ — authored to E-E-A-T research standards with full citation of primary literature.
Wound Healing Phase Timeline — Which Compounds When
Wound healing proceeds through three overlapping phases, each dominated by distinct cellular processes. Hub compounds have different phase-activity profiles — understanding this enables rational sequencing rather than applying maximum compounds simultaneously throughout recovery.
Phase 1
Inflammatory
Days 0 – 4
LL-37
Antimicrobial clearance of biofilm and bacterial contamination; EGFR-mediated early re-epithelialization signaling; modulateshost inflammatory resolution cascade
Early nitric oxide system modulation; GI mucosal protection if wound is stress-related; initial VEGFR2 priming for the angiogenic phase to follow
Phase 2
Proliferative
Days 5 – 21
BPC-157 — peak phase
VEGFR2/NO angiogenesis drives new vessel formation; fibroblast migration and activation for granulation tissue; spans all three phases but dominates the proliferative window
TB-500
G-actin sequestration enables keratinocyte and fibroblast migration across wound bed; VEGF-A upregulation; stem cell mobilization to repair site from bone marrow reservoirs
GHK-Cu
Growth factor induction (TGF-β, bFGF, VEGF from macrophages); copper-dependent lysyl oxidase activation begins cross-linking initial collagen scaffolding throughout proliferative phase
Phase 3
Remodeling
Month 1 – Year 2
GHK-Cu — primary phase
Bidirectional "smart" MMP regulation — breaks down disorganized scar collagen while stimulating new type I/III synthesis; determines final collagen quality and scar vs. normal skin outcome
Epithalon
TERT/telomerase activation sustains fibroblast replicative capacity across the extended remodeling window; SASP reduction limits chronic inflammatory signaling that degrades repair quality in older patients
BPC-157
Continued anti-fibrotic signaling limits excess collagen deposition; sustained angiogenic maintenance; GI mucosal protection during prolonged systemic recovery
Sequencing Implication: LL-37 delivers maximum value in the first 72–96 hours (antimicrobial/inflammatory). BPC-157 and TB-500 are most active during weeks 1–3 (proliferative). GHK-Cu is effective across all phases but is uniquely irreplaceable in the remodeling months, where collagen quality determination occurs. Rational sequencing — rather than simultaneous maximum-compound application — reduces cost and complexity while maintaining mechanistic coverage of each phase.
Clinical Decision Support
Choosing the Right Compound by Indication
Hub compounds address overlapping but distinct clinical scenarios. The table below maps primary indications to first-line, second-line, and adjunctive compound selections based on the current evidence hierarchy — not commercial availability or anecdote.
LL-37 central to rosacea pathophysiology; KPV preclinical anti-inflammatory in skin; GHK-Cu in vitro NF-κB data
Evidence Hierarchy Caveat: "First-line" rankings above reflect the strength of published research evidence for that compound in that indication — not FDA approval status. Most hub compounds have limited-to-no approved human indications. Clinical decision-making should involve a qualified physician with appropriate specialty expertise and awareness of regulatory status in your jurisdiction.
Combination Protocols
Rational Combination Strategies
Hub compounds are frequently used in combination because their mechanisms are complementary rather than redundant. The most evidence-informed combinations target multiple steps in the wound healing or tissue repair cascade simultaneously — angiogenesis, collagen synthesis, anti-inflammation, and remodeling are distinct processes that different compounds address through non-overlapping pathways.
Anti-Aging Skin Protocol
Collagen Restoration Stack
GHK-CuEpithalonRetinoids
GHK-Cu applied topically once to twice daily for collagen synthesis stimulation and ECM remodeling. Epithalon added for telomere-length support and systemic anti-aging signaling (SC or intranasal). Retinoids (tretinoin or retinol) applied in alternating time-of-day application from GHK-Cu to avoid pH-chelation interference. Mechanistic rationale: GHK-Cu works on matrix; Epithalon works on cellular aging clock; retinoids increase cell turnover — three distinct and additive mechanisms.
GHK-Cu applied topically to wound area for collagen synthesis, TGF-β/VEGF induction, and anti-inflammatory support. BPC-157 administered SC peripherally for systemic wound healing signaling, angiogenesis (VEGFR2/NO), and gastrointestinal mucosal protection if applicable. LL-37 added topically if biofilm or antimicrobial concern is present. Requires physician supervision for wound management — not appropriate for self-directed use.
BPC-157 SC for angiogenesis, fibroblast activation, and tendon-specific healing (strongest evidence in this combination). TB-500 SC for actin dynamics, stem cell mobilization, and VEGF-A-driven repair — acts on different cellular targets than BPC-157. GHK-Cu topically over the injury site for local collagen synthesis support. WADA note: TB-500 is prohibited in competition athletes; BPC-157 is not currently listed but check annually. All three are investigational in humans for sports applications.
Preclinical evidence for BPC-157 + TB-500 synergy in acute injury models; GHK-Cu provides collagen quality support at the repair site
Post-Microneedling / Aesthetic
Procedure Enhancement Stack
GHK-CuPRP (autologous)EGF / Growth Factors
GHK-Cu applied immediately post-microneedling while channels are open — capitalizes on 5–40× enhanced dermal delivery vs. intact skin application. PRP applied during procedure for platelet-derived growth factor delivery (PDGF, TGF-β, VEGF from platelets). GHK-Cu then provides the copper-dependent lysyl oxidase activation that growth factors cannot supply themselves — enzymes needed to correctly cross-link the new collagen that growth factors induce. EGF or FGF serums can be incorporated in the post-procedure days 2–7 window.
GHK-Cu scalp solution (2–5%) twice daily for follicle enlargement and hair density (Naughton 1994 evidence). Topical minoxidil 2–5% (separate application time — morning vs. evening — to avoid formulation interaction). Oral finasteride or dutasteride for DHT suppression addressing the hormonal driver of androgenetic alopecia. Monthly or biweekly scalp microneedling (0.5–1 mm) to enhance GHK-Cu delivery and provide direct follicular stimulation. This four-component protocol addresses androgenesis, follicle-level growth factors, DHT pathway, and mechanical stimulation simultaneously.
Epithalon for telomerase (TERT) activation and telomere elongation — addressing the cellular clock directly. GHK-Cu for senescent fibroblast phenotype reversal — downregulates SASP (senescence-associated secretory phenotype) inflammatory cytokines in aged fibroblasts while upregulating survival and repair gene expression. Complementary anti-aging targets: Epithalon at the telomere/nucleus level; GHK-Cu at the secretory phenotype/extracellular matrix level. Combined, they address two of the most mechanistically validated pathways in skin aging biology.
Phase III equivalent (wound); commercial cosmetic use
BPC-157 Gastric Pentadecapeptide
Moderate (Animal)
Very Strong (Animal)
Early
Multiple controlled animal RCTs across tissues; PL-10 Phase II (IBD)
Phase II (IBD); no human tissue repair trials
TB-500 Thymosin β4 Fragment
Early
Moderate (Animal)
Early
Animal cardiac recovery models (Thymosin β4); LKKTETQ fragment limited
Thymosin β4 Phase II (MI, dry eye); TB-500 fragment: no human trials
Epithalon AEDG Tetrapeptide
Moderate
Early
Moderate–Strong
Khavinson human studies (telomere, skin, longevity markers); limited independent replication
Russian clinical research; Western RCT replication limited
LL-37 Human Cathelicidin
Strong (Mechanistic)
Moderate
Early
Phase II wound healing (LL-37 recombinant, venous leg ulcers, Lipopeptides); human exogenous trials
Phase II (wound healing); pathophysiology central to rosacea/psoriasis
KPV α-MSH Tripeptide
Early
Early
Early
In vitro MC1R studies; animal IBD models; no human RCTs
Preclinical; no human trials
Safety & Regulatory Reference
Regulatory Status & Safety Matrix
Physician due diligence requires a consolidated view of FDA status, WADA classification, administration routes, and key safety flags for all hub compounds. This matrix provides that reference in a single table — required reading before any clinical consideration of these investigational agents.
Copper overload theoretical but extremely low risk with topical use — systemic absorption minimal. SC use: monitor serum copper and ceruloplasmin. Contraindicated in Wilson's disease. No known drug interactions for topical application.
Topical: commercial cosmetic products widely available. Injectable: compounding pharmacy (503A) or overseas research grade. No FDA-approved injectable formulation.
BPC-157 Gastric Pentadecapeptide
Investigational Phase II (IBD); no approved indication
Not Listed
SC injection; oral (limited systemic, possible GI-specific effect)
No serious adverse events in extensive animal models or Phase II data. Extremely limited long-term human safety data. FDA 2024: Removed from 503A bulk substance candidate list — traditional US compounding pharmacies cannot use as bulk ingredient. Verify pharmacy compliance status before sourcing.
FDA 2024 restriction limits 503A compounding. Overseas research chemical sources exist. Regulatory status evolves — verify current FDA guidance at time of any clinical consideration.
TB-500 Thymosin β4 Fragment
Investigational Full Tβ4 Phase II; fragment no trials
WADA Prohibited S2 Peptide Hormones & Related Substances
SC injection; IV (clinical settings only)
Athletes in sanctioned sports: WADA S2 prohibition triggers disqualification and ban. Limited human safety data for LKKTETQ fragment specifically. Full-length Tβ4 well-tolerated in Phase II cardiac/dry eye trials. Potential immunomodulatory effects not fully characterized. Exact elimination half-life for WADA testing purposes not established for the fragment.
Research chemical grade; overseas suppliers. Not typically available through US compounding pharmacies for performance or repair indications. Full Thymosin β4 available through clinical trial access only.
Epithalon AEDG Tetrapeptide
Investigational No Western regulatory approval
Not Listed
SC injection; intranasal spray; topical (limited)
Favorable safety profile across decades of Khavinson clinical use in Russian populations. Lacks Western regulatory safety trial data. Theoretical oncology concern: telomerase activation in cancer cells — not supported by current normal-cell evidence, but standard practice is to avoid in patients with active or recent malignancy. No significant adverse events reported in published Khavinson studies.
Research grade from overseas suppliers; some US compounding pharmacies carry intranasal or injectable formulations. Not FDA-approved. Verify compounding status.
LL-37 Human Cathelicidin
Investigational Phase II (wound healing, venous ulcers)
Concentration-dependent cytotoxicity is the primary safety concern — antimicrobial activity at 1–10 μg/mL; host cell toxicity begins above 50–100 μg/mL in vitro. Formulation must achieve therapeutic window. Endogenous overexpression associated with rosacea and psoriasis pathology — context matters (deficiency vs. excess). Limited systemic safety data for exogenous administration.
Synthetic recombinant; research grade. Compounding pharmacies (topical formulations). No commercial approved product in US. Formulation expertise required to achieve appropriate concentration range.
KPV α-MSH C-terminal Tripeptide
Preclinical No human trials; in vitro / animal only
Not Listed
Topical; oral (IBD research formulations); SC (preclinical)
MC1R agonism generally associated with favorable safety profile (receptor present on melanocytes, keratinocytes, macrophages). No human safety data. Small size (~339 Da) enables potential systemic absorption from topical formulations — extent not characterized. No reported serious adverse events in preclinical models.
Research chemical grade; very limited pharmaceutical-grade supply. Not typically available through US compounding pharmacies. Primarily overseas research sources.
Regulatory Status Evolves Rapidly: This table reflects best available information at time of authorship (2026). Peptide regulatory designations — especially FDA 503A bulk substance lists — change frequently. BPC-157's 2024 removal from the 503A candidate list is a recent example of how quickly sourcing pathways can change. Always verify current FDA, state pharmacy board, and WADA status before any clinical consideration. PeptideReport.ai is not a regulatory authority and this table does not constitute legal or regulatory guidance.
Practical Administration Reference
Formulation & Administration Guide
Pharmacokinetic properties determine how each compound must be prepared, stored, and administered to maintain bioactivity. The practical considerations below cover stability, reconstitution, storage, and key formulation caveats for each hub compound — the information a prescribing physician and compounding pharmacist need to know.
GHK-Cu
Topical Primary · SC Investigational
pH stability: Copper peptide complex stable at pH 4.5–6.5. Avoid combining with high-concentration vitamin C (ascorbic acid competes for copper chelation at low pH, reducing GHK-Cu bioactivity in the same formulation). Storage: Refrigerated 2–8°C preferred; commercial topical formulations stable at room temperature 3–6 months in opaque packaging. Injectable route: Occasionally used in investigational settings only — not an FDA-approved route for GHK-Cu, and reconstitution or dosing specifics are outside the scope of this reference; physician- and compounding-pharmacist-directed only. Vehicle consideration: Hyaluronic acid base enhances dermal retention; penetration enhancers (DMSO, ethosomes, liposomes) increase stratum corneum transit but may alter copper release kinetics. The ~402 Da molecular weight enables meaningful intact-skin penetration without enhancers at standard topical concentrations.
BPC-157
SC Injection · Oral (GI-specific activity)
Stability: Lyophilized powder very stable (months to years at room temperature); reconstituted solution: 28–30 days refrigerated, protect from light and repeated temperature change. Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) preferred for multi-dose vials; sterile water for single-use. pH tolerance: Stable across pH 4–9 — tolerant of most pharmaceutical vehicles. Oral route: Capsule formulations exist with reduced systemic bioavailability vs. SC administration but may offer GI mucosal specificity for GI-targeted applications. Injection amount, frequency, and course length are physician-directed decisions outside the scope of this reference.
TB-500
SC Injection · IV (clinical settings only)
Stability: Lyophilized LKKTETQ peptide moderately stable; more oxidation-sensitive than GHK-Cu. Storage: Lyophilized: −20°C long-term; 4°C up to 3 months; avoid repeated freeze-thaw cycles which promote aggregate formation. Reconstitution: Bacteriostatic water 0.9% is the standard diluent for lyophilized peptide powders of this class. Avoid: Metal-contaminated containers (promotes oxidation of the peptide's sulfur-containing residues). Injection amount, frequency, and course length are physician-directed decisions outside the scope of this reference. WADA consideration: Exact elimination timeline for LKKTETQ fragment not established in published literature; WADA immunoassay may cross-react with endogenous Thymosin β4 — athletes must account for both. Consult sports medicine physician before any use.
Epithalon
SC Injection · Intranasal · Topical
Stability: Very stable tetrapeptide — excellent thermal stability and pH resistance across a wide range. Storage: Lyophilized: room temperature acceptable short-term; refrigerated preferred. Reconstituted: 2–8°C; multi-week stability. Injectable route: Investigational only, not FDA-approved, and reconstitution or dosing specifics are outside the scope of this reference — physician-directed only. Intranasal: Spray formulations offer faster CNS/pituitary access than SC administration for pineal-targeted applications; specific dosing is likewise a physician-directed decision. Topical: ~390 Da permits some dermal penetration; 1–3% concentration in water-based serum for skin applications. Administration pattern: Khavinson's published research used intermittent rather than continuous administration, on the rationale that this better mimics natural peptide signaling rhythms and allows receptor sensitivity recovery — specific protocol design remains a matter for physician-directed research rather than self-administration.
LL-37
Topical Primary · Intranasal (research)
Stability: Linear 37-residue peptide with susceptibility to proteolytic degradation in wound environments (serine proteases, matrix metalloproteases). Encapsulation substantially improves stability and therapeutic index. Storage: Lyophilized: −20°C required; reconstituted: use within 7 days at 4°C — among the least stable hub compounds in solution. Concentration window (critical): Antimicrobial activity at 1–10 μg/mL; host cell cytotoxicity begins above 50–100 μg/mL in vitro — the therapeutic window is narrow. Liposome or nanoparticle encapsulation enables sustained-release formulations that maintain the therapeutic concentration range while protecting against degradation. pH consideration: Activity maintained pH 5.5–8.0; wound pH is highly variable and affects peptide charge state and membrane activity.
KPV
Topical · Oral IBD Research
Stability: Exceptionally stable tripeptide — excellent thermal stability and resistance to enzymatic degradation due to small size and absence of complex secondary structure. Storage: Lyophilized powder stable at room temperature; reconstituted solutions similarly stable compared to larger peptides. Topical penetration: At ~339 Da the smallest compound in the hub — excellent percutaneous penetration through intact stratum corneum without penetration enhancers. Extent of systemic absorption from topical formulations not well-characterized. Oral IBD research: Hydrogel microsphere and mucoadhesive formulations under investigation for colon-specific delivery (murine colitis models show efficacy); systemic oral bioavailability not characterized. Availability note: Pharmaceutical-grade supply very limited; current sourcing primarily research chemical grade only.
Frequently Asked Questions
Skin & Repair Hub — Common Questions
Is GHK-Cu or BPC-157 more appropriate for wound healing?
For skin wounds specifically, GHK-Cu has the stronger human clinical evidence — Phase III-equivalent controlled trials (Abdulghani 1998) confirming wound area reduction, re-epithelialization rate improvement, and histologically verified collagen deposition. BPC-157 has very strong preclinical evidence across multiple tissue types but lacks published human wound healing RCTs. GHK-Cu is also dramatically easier to deliver topically (small ~402 Da; validated topical formulations), while BPC-157 is typically administered SC for systemic wound healing effects.
The rational approach for complex wounds is GHK-Cu topically (proven topical delivery; RCT evidence) combined with BPC-157 SC (systemic angiogenesis, gastrointestinal protection if relevant), under physician supervision. For straightforward cosmetic wound healing (post-procedure aesthetic), GHK-Cu alone with established topical protocols is appropriate first.
Can compounds from this hub be combined safely?
No formal drug-drug interaction studies exist for hub compound combinations, because none are approved pharmaceuticals with interaction databases. What is known: the compounds' mechanisms are largely non-overlapping, making pharmacological antagonism unlikely. GHK-Cu (copper delivery, growth factor induction), BPC-157 (VEGFR2/NO), TB-500 (actin dynamics/VEGF-A), and Epithalon (telomerase) operate through distinct molecular targets.
However, absence of studied interactions is not equivalence to proven safety in combination. Each compound individually has a reasonable safety record in published research; combined use introduces untested complexity. Physician oversight of any combination protocol is appropriate, particularly for systemic routes (SC administration). Topical combinations (GHK-Cu + retinoids, for example) have more established precedent in clinical dermatology practice.
What is the evidence quality difference between GHK-Cu and BPC-157?
This is one of the most important distinctions in the hub. GHK-Cu has genuine human RCT evidence — randomized controlled trials with placebo comparators in human subjects, published in peer-reviewed dermatology journals. This is a qualitatively different evidence standard than animal model data, however compelling. BPC-157 has extensive, well-controlled animal research across multiple species and tissue types, and is in Phase II human trial for one indication (inflammatory bowel disease, PL-10), but has no published human RCTs for wound healing, tissue repair, or any of the indications most commonly discussed in the research community.
The evidence hierarchy matters: GHK-Cu for wound healing and skin anti-aging represents claims backed by human clinical evidence. BPC-157 for tendon healing and tissue repair represents extrapolation from robust animal data — a legitimate and common basis for investigational use, but a meaningfully different epistemic status.
How does microneedling improve GHK-Cu delivery?
Microneedling creates thousands of temporary microchannels through the stratum corneum — the primary physical barrier to intact peptide delivery. GHK-Cu's ~402 Da molecular weight is favorable for transdermal penetration through intact skin (below the ~500 Da cutoff), but dermal fibroblast concentrations are higher when the barrier is transiently disrupted.
Quantified estimates suggest 5–40× enhanced delivery through microneedling channels vs. standard topical application on intact skin. The enhancement depends on needle depth (0.25–2 mm range used in practice), GHK-Cu concentration in the vehicle, and time of application post-needling (channels begin closing within 30–60 minutes). This is not unique to GHK-Cu — all topically applied actives benefit from microneedling channel delivery — but GHK-Cu's dermal fibroblast target makes the enhanced depth penetration particularly valuable, since fibroblasts reside in the dermis, not the epidermis.
Is TB-500 the same as Thymosin β4?
TB-500 and Thymosin β4 are related but distinct. Thymosin β4 is the full-length endogenous 43-amino acid protein present in virtually all nucleated human cells. TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin β4 — the 7-amino acid fragment LKKTETQ (residues 17–23). This fragment contains the key G-actin sequestration sequence responsible for most of Thymosin β4's effects on actin dynamics, cell migration, and tissue repair signaling.
Most of the biological activity attributed to Thymosin β4 is thought to reside in this fragment, which is why TB-500 (or LKKTETQ peptide) became the research compound of interest — it is smaller, more synthetically accessible, and more stable. However, full-length Thymosin β4 may have additional activities not recapitulated by the fragment alone. The human trial evidence (MI, dry eye) uses full-length Thymosin β4; TB-500 as LKKTETQ has no standalone human clinical trial evidence.
Why does GHK-Cu decline with age, and does this explain skin aging?
GHK-Cu plasma levels decline from approximately 200 ng/mL in young adults to as low as 20 ng/mL in the elderly — a loss of ~90% over the lifespan. The mechanism of this decline is not fully elucidated; leading hypotheses involve reduced generation of GHK from its precursor proteins (collagen and albumin fragments) during tissue remodeling, as well as increased clearance or metabolic inactivation.
Whether this decline causally explains skin aging, or is merely correlative (both the decline and skin aging arising from the same underlying biology of reduced tissue turnover), remains an open scientific question. What is established is the temporal parallel between GHK-Cu decline, collagen loss (~1%/year starting mid-20s), and deteriorating wound healing capacity. The biological rationale for topical or systemic GHK-Cu supplementation rests on this parallel — the hypothesis that restoring youthful GHK-Cu tissue concentrations restores some component of youthful tissue maintenance signaling. This is a plausible and mechanistically supported hypothesis, but direct proof of causality in humans requires longitudinal supplementation trials with aging biomarkers as outcomes, which have not been conducted.
About This Hub
Skin & Repair Hub — Category FAQ
What peptides does the Skin & Repair Hub cover?
This hub profiles six peptides studied for wound healing, skin regeneration, and connective tissue repair: GHK-Cu, BPC-157, TB-500, Epithalon, LL-37, and KPV. They are grouped here by shared mechanisms — extracellular matrix remodeling, angiogenesis, anti-inflammatory modulation, and growth factor upregulation — rather than by administration route or commercial category. Each compound has its own full research profile linked from this page, and the hub itself provides the comparative evidence summary, decision framework, and safety matrix across all six.
Is GHK-Cu legal, and how is it regulated compared to the hub's other compounds?
GHK-Cu is the only hub compound with a recognized cosmetic-ingredient status: it is INCI-listed and appears in over-the-counter topical skincare products. Injectable or subcutaneous use of GHK-Cu is a separate matter — that route is investigational, not FDA-approved for any indication, and not addressed by this page. The other five hub compounds (BPC-157, TB-500, Epithalon, LL-37, KPV) hold no cosmetic-ingredient status and are classified investigational or preclinical across all routes. Regulatory status changes over time, so current FDA and state pharmacy board guidance should be checked directly rather than assumed from this page.
What does the evidence show for skin and wound-healing peptides as a category?
Evidence quality varies widely across the category rather than being uniform. Among hub compounds, GHK-Cu carries the strongest human evidence, including placebo-controlled trial data for wound healing and skin anti-aging. BPC-157, TB-500, and KPV rest primarily on animal or in-vitro data with limited-to-no human trials for skin or repair indications. LL-37 has strong mechanistic grounding plus Phase II human wound-healing data, and Epithalon draws on decades of Russian clinical research with limited independent Western replication. As a category, mechanistic and preclinical support currently outweighs confirmed human clinical outcomes for most of these compounds.
What's the difference between topical and injectable use of these peptides in terms of evidence and safety?
Topical formulations — such as GHK-Cu serums or LL-37 preparations — generally have a more established safety record because systemic absorption is limited and, for GHK-Cu, commercial cosmetic use has years of consumer-product precedent. Injectable or subcutaneous routes discussed across the hub are investigational for every compound, lack FDA approval for the indications covered here, and depend on physician oversight and compounding-pharmacy sourcing that is itself subject to change — BPC-157's 2024 removal from the FDA's 503A bulk substance candidate list is one example. This page does not provide injectable dosing instructions; any decision about administration route belongs to a supervising physician.
What should I look for in a legitimate cosmetic peptide product, such as a GHK-Cu skincare formula?
Look for the peptide listed by its INCI name (for example, "Copper Tripeptide-1" for GHK-Cu), a stated concentration rather than a vague "peptide complex" label, and a manufacturer able to provide sourcing or stability documentation. For GHK-Cu specifically, formulation matters: pairing it in the same product with high-concentration vitamin C can reduce activity, since ascorbic acid competes for copper at low pH. Marketing that implies a cosmetic product carries injectable-grade purity or clinical-trial backing should be treated with skepticism — cosmetic and investigational/injectable supply chains are regulated separately and are not interchangeable claims.
Are the peptides in this hub interchangeable, or does the right one depend on the indication?
They are not interchangeable. Although hub compounds share overlapping mechanisms — matrix remodeling, angiogenesis, anti-inflammatory signaling — each has a different evidence profile and area of relative strength: GHK-Cu leads on human wound-healing and skin anti-aging data, BPC-157 and TB-500 lead on tendon and soft-tissue repair evidence in animal models, LL-37 is mechanistically central to antimicrobial and inflammatory skin conditions, and Epithalon and KPV occupy narrower, earlier-stage research niches. The hub's decision framework table above maps common indications to first-line and adjunctive compound choices based on current published evidence.
Full Research Disclaimer
The compounds profiled in the Skin & Repair Hub are not approved by the U.S. Food and Drug Administration as pharmaceutical drugs for the indications discussed, with the exception of conventional treatments referenced for comparison (minoxidil, finasteride, tretinoin). Information on this page and in linked profiles is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Research literature cited reflects published evidence at time of authorship; evidence classifications and regulatory status evolve. Clinical applications described are drawn from published research and do not represent prescribing guidance. Wound care applications require physician supervision. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparation. All clinical decisions — including any consideration of the compounds discussed here — should involve a qualified healthcare professional with appropriate specialty expertise.
SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai
Dr. Scott DelBoccio, DMD brings a physician-scientist perspective to peptide pharmacology research. The Skin & Repair Hub represents a curated collection of the regenerative and wound-healing peptides with the most clinically substantive evidence bases — profiled to E-E-A-T research standards with primary literature citation. PeptideReport.ai was founded on the principle that physician-authored, evidence-calibrated content is the appropriate standard for this emerging research space. No commercial relationships with peptide manufacturers or distributors. All compound profiles are research literature reviews, not clinical guidance or treatment endorsements.